Chronic Myeloid Leukemia (CML) Cohort
- Determine the impact of current procedures for diagnosis, management, and follow-up on
disease status of patients with newly diagnosed chronic myelogenous leukemia (CML).
- Determine the natural history of patients with CML who achieve response to imatinib
- Determine the health perceptions, symptoms, insurance issues, and work issues of these
- Determine whether medication compliance and planned dose reduction affect imatinib
mesylate effectiveness in these patients.
- Determine the molecular and biologic factors associated with disease progression and
good and poor response to imatinib mesylate in these patients.
OUTLINE: This is a longitudinal, prospective, cohort study.
Patients complete quality of life, functional status, medical and treatment history, and
medication questionnaires at baseline and then every 6 months for 5 years.
Blood samples are collected at baseline and then every 6 months for 5 years. Specimens may
be examined in the future in gene array studies and mutation analyses.
PROJECTED ACCRUAL: A total of 2,000 patients will be accrued for this study within 2 years.
Impact of current procedures for diagnosis, management, and follow-up on disease status
Jerome Ritz, MD
Dana-Farber Cancer Institute
United States: Federal Government
|Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute||Boston, Massachusetts 02115|